Vertex licenses its first drug from CRISPR collaboration – BioPharma Dive
Labiotech.eu |
Vertex licenses its first drug from CRISPR collaboration
BioPharma Dive Vertex Pharmaceuticals Inc. has selected CTX001 as the first drug it will co-develop and commercialize with CRISPR Therapeutics AG per the companies’ ongoing collaboration. Executives have already requested from regulators to conduct a Phase 1/2 trial … Vertex and CRISPR Therapeutics Partner on Gene Therapy for Blood DisordersBioPharm International Global CRISPR/Cas9 Tools Market Opportunity & Insights Report 2017Markets Insider Crispr Therapeutics (CRSP) vs. Immunomedics (IMMU) Critical AnalysisWeek Herald The Lincolnian Online all 12 news articles » |
|
Immunotherapy, gene editing advances extend to Type 1 Diabetes
Medical Xpress Dr. Jane Buckner of the Benaroya Research Institute at Virginia Mason and Dr. David Rawlings at Seattle Children’s Research Institute are leading research to develop an immunotherapy for type 1 diabetes. Credit: Seattle Children’s. Advances in … |